Our CDSO and Cofounder, Layla Hosseini-Gerami, has been featured in The Biochemist. The article details her journey in the field of data science, the challenges and rewards of her role, and the exciting work we are doing at Ignota Labs.
“I studied for a MChem/BSc in chemistry at the University of Leeds, but realized that I didn’t enjoy the lab as much as I thought and I wasn’t sure what to do next. Thankfully, I ended up landing a year in industry placement in computational chemistry at Optibrium in my third year. While I was there, I developed algorithms to accurately predict the pKa of small molecules and had the opportunity to present and publish my work. I went on to develop my skills further during a PhD in chemoinformatics/bioinformatics and machine learning, in Andreas Bender’s group at the University of Cambridge. I worked on causal reasoning methods for using multi-modal data to understand drug mode of action (MoA). I joined Ignota Labs in February 2022 and built the company from the ground up along with two cofounders Jordan and Sam, while writing up my PhD. Ignota Labs is focused on using explainable AI methods to predict, understand and turnaround safety issues in drug discovery. Ignota Labs went full-time in October 2023 and since then we have made big technical and commercial progress,” Dr. Layla Hosseini-Gerami.
Read more:
‘A day in the life of a Chief Science Officer and Cofounder of Ignota Labs’ can be read in full at the Biochemist.
Published: 3 May 2024 by Portland Press
